Eckert & Ziegler AG

WHO'M
ai
Digital Profiler. Simply click the AI button
CUSIP

D2371P107
SEDOL

5689857
CIK

N/A

ezag.com
LEI: 391200EUDABLUKXCKG48
FIGI: BBG000BSBF36
EUZ

Eckert & Ziegler AG
GICS: 35101010 · Sector: Medical equipment · Sub-Sector: -
AI
PROFILER
NAME
Eckert & Ziegler AG
ISIN
DE0005659700
TICKER
EUZ
MIC
XETR
REUTERS
EUZG.DE
BLOOMBERG
EUZ GR
FOR INVESTORS
FOR TRADERS
Securities Trading Warrants
EQS Newswire is a major provider of regulatory and corporate news. It mainly serves companies, investors and media worldwide. Through its services, EQS Newswire enables efficient and secure communication between companies and their stakeholders. Its main services include the distribution of ad hoc announcements, corporate news and the publication of financial reports that meet strict international standards.
Thu, 27.03.2025

Berlin, 27 March 2025. Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) achieved a new record in the 2024 financial year with sales of € 295.8 million based on the preliminary annual financial statements*. Compared to the previous year, sales increased by almost € 50 million (+20%). EBIT before special items from continuing operations (adjusted ...
Tue, 25.03.2025

Berlin, DE & New York, USA, 25 March 2025. Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) and Actinium Pharmaceuticals, Inc. announced that they have entered into an agreement for the supply of Actinium-225 (Ac-225). With this agreement, Actinium Pharmaceuticals will have access to Eckert & Ziegler’s high-purity Actinium-225 to further...
Thu, 20.03.2025

Berlin, DE & Hamilton, ON, CA, 20 March 2025. Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) and AtomVie Global Radiopharma Inc. (AtomVie) today announced a global supply agreement. Eckert & Ziegler will provide its high-quality non-carrier added Lutetium-177 chloride (n.c.a. Lu-177, Theralugand®) to support AtomVie’s CDMO activities f...
Thu, 27.02.2025

Berlin, Germany, 27 February 2025. Eckert & Ziegler SE (ISIN DE0005659700, TecDAX), a leading provider of isotope technology for medical, scientific, and industrial use, today announced a comprehensive strategic partnership with Bicycle Therapeutics (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeuti...
Tue, 25.02.2025

Berlin, 25 February 2025. Following a cyber-attack on the IT infrastructure of Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) at the beginning of February, the Group's business operations can continue in most areas. In a few cases, there are still restrictions due to the gradual restoration at one point or another.  As of this week, all essent...
Thu, 13.02.2025

Berlin, 13 February 2025. Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) has suffered a cyber attack on parts of its IT systems. The systems were temporarily shut down proactively and disconnected from the internet to minimise any potential impact. The IT systems and the effects of the attack are currently being examined. The utmost care is be...
Mon, 03.02.2025

Press Release    IT Incident Affects Eckert & Ziegler SE's Communication Channels   Berlin, 03 February 2025. Due to an unexpected IT incident, Eckert & Ziegler is currently unable to receive emails or phone calls. We understand the inconvenience this may cause and want to assure our customers and partners that we are working diligently to ...
Mon, 27.01.2025

Financial Year 2024 (preliminary): Sales of around EUR 295 million (previous year:  EUR 246.1 million) EBIT before special items of around EUR 66 million (previous year: EUR 46.9 million) Net Income of around EUR 33 million (previous year: EUR 26.3 million) Berlin, 27 January 2025. According to preliminary, unaudited figures, Eckert & Ziegle...
Tue, 14.01.2025

Berlin, 14 January 2025. Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) today signed a licence agreement with Qi Kang Medical, Ltd (QKM), a joint venture between Eckert & Ziegler and the Chinese company DC Pharma, for the cyclotron technology used by Eckert & Ziegler to manufacture Ac-225. The contract guarantees Eckert & Ziegler a...
Mon, 13.01.2025

Berlin, Germany and Sydney, Australia, 13. January 2025. Eckert & Ziegler (ISIN DE0005659700, SDAX) and GlyTherix Ltd (GlyTherix), an Australian targeted radiotherapy company specialising in developing antibody radiopharmaceuticals for solid tumors, today announced the expansion of their existing Lutetium-177 based collaboration with a global s...
We are different
OPEN FINANCIAL
DATA & KNOWLEDGE HUB
We make the difference
Information on product placements

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S